Transmission-blocking vaccine against malaria
AssigneesThe United States of America as represented by the Department of Health and Human Services, Chiron Corporation
InventorsDavid C. Kaslow, Philip J. Barr
Life of this patent
Estimating the term…
Abstract
The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.
Claims13
A vaccine for reducing the sexual development of Plasmodium falciparum within a mosquito comprising a Pfs25 Plasmodium falciparum protein, wherein the Pfs25 protein lacks a native N-terminal secretory sequence and a native hydrophobic carboxy-terminal region, wherein vaccine elicits antibodies that recognize the Pfs25 Plasmodium falciparum protein and the antibodies are capable of reducing the sexual development of Plasmodium falciparum within a mosquito.
Dependencies are inferred from the claim text.